enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. ALK inhibitor - Wikipedia

    en.wikipedia.org/wiki/ALK_inhibitor

    ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. [1] They fall under the category of tyrosine kinase inhibitors , which work by inhibiting proteins involved in the abnormal growth of tumour cells.

  3. Targeted therapy of lung cancer - Wikipedia

    en.wikipedia.org/.../Targeted_therapy_of_lung_cancer

    Inhibitors of vascular endothelial growth factor (VEGF) [13] bevacizumab (Avastin) [14] [unreliable medical source?] Inhibitor of EML4-ALK. crizotinib shows benefit in a subset of non-small cell lung cancer that is characterized by the EML4-ALK fusion oncogene, [15] [16] found in some relatively young, never or light smokers with adenocarcinoma ...

  4. Anaplastic lymphoma kinase - Wikipedia

    en.wikipedia.org/wiki/Anaplastic_lymphoma_kinase

    It restricts and constrains learning and long-term memory [27] [55] [44] and small-molecule inhibitors of the ALK receptor can improve learning, [27] long-term memory, [55] and extend healthy lifespan. [56] ALK is also a candidate thinness gene, as its genetic deletion leads to resistance to diet- and leptin-mutation-induced obesity. [57] [N 1]

  5. Ceritinib - Wikipedia

    en.wikipedia.org/wiki/Ceritinib

    Ceritinib is an anaplastic lymphoma kinase (ALK) inhibitor primarily used for the treatment of ALK positive metastatic NSCLC. [8] [9] Previously, it was only indicated for patients who had developed resistant to crizotinib, another ALK inhibitor, but has since had its usage expanded to serve as a primary option for metastatic NSCLC.

  6. Treatment of lung cancer - Wikipedia

    en.wikipedia.org/wiki/Treatment_of_lung_cancer

    Crizotinib shows benefit in a subset of non-small cell lung cancer that is characterized by the EML4-ALK fusion oncogene, [24] and is approved by the FDA. [25] EML4-ALK is found in some relatively young, never or light smokers with adenocarcinoma. [26] Advances in cytotoxic drugs, [27] pharmacogenetics [28] and targeted drug design [29] show ...

  7. Ensartinib - Wikipedia

    en.wikipedia.org/wiki/Ensartinib

    Ensartinib, sold under the brand name Ensacove, is an anti-cancer medication used for the treatment of non-small cell lung cancer. [1] Ensartinib is an Anaplastic lymphoma kinase (ALK) inhibitor used as the salt ensartinib hydrochloride. [1] It is taken by mouth. [1]

  8. Brigatinib - Wikipedia

    en.wikipedia.org/wiki/Brigatinib

    Brigatinib is an inhibitor of ALK [3] and mutated EGFR. [5]ALK was first identified as a chromosomal rearrangement in anaplastic large cell lymphoma (ALCL). Genetic studies indicate that abnormal expression of ALK is a key driver of certain types of non-small cell lung cancer (NSCLC) and neuroblastomas, as well as ALCL.

  9. Crizotinib - Wikipedia

    en.wikipedia.org/wiki/Crizotinib

    National Cancer Institute. "Crizotinib". National Cancer Institute. 11 October 2011. Clinical trial number NCT00585195 for "A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)" at ClinicalTrials.gov